Literature DB >> 9863601

A family with mental retardation, variable macrocephaly and macro-orchidism, and linkage to Xq12-q21.

J P Johnson1, R Nelson, C E Schwartz.   

Abstract

A family with X linked inheritance of mental retardation (XLMR) is presented. There are 10 mentally retarded males and two affected females in two generations. There are four obligatory carriers, one of whom is described as "slow". Most affected males show macrocephaly and macro-orchidism, which are typical signs of the fragile X syndrome, but have been tested cytogenetically and by analysis of the FMR1 gene and do not have this syndrome. However, some normal males in the family also exhibit macro-orchidism and macrocephaly. Linkage analysis using markers derived from the X chromosome indicates that the causative gene in this family is located in the proximal long arm of the X chromosome, in the interval Xp11-q21. Maximum lod scores of 2.96 with no recombination were found at three loci in Xq13-q21: DXS1111, DXS566, and DXS986. Recombination was observed with DXS1002 (Xq21.31) and DXS991 (Xp11.2), loci separated by about 30 Mb. Although isolation of the gene in this family will be difficult because of the size of the region involved, the localisation should be helpful in investigating other similar families with XLMR, macrocephaly, and macro-orchidism not attributable to FMR1.

Entities:  

Mesh:

Year:  1998        PMID: 9863601      PMCID: PMC1051516          DOI: 10.1136/jmg.35.12.1026

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  21 in total

1.  Recurrent myoglobinuria in a child with mental retardation: phosphoglycerate kinase deficiency.

Authors:  H Sugie; Y Sugie; M Nishida; M Ito; S Tsurui; M Suzuki; R Miyamoto; Y Igarashi
Journal:  J Child Neurol       Date:  1989-04       Impact factor: 1.987

2.  X-linked mental retardation.

Authors:  G Turner; B Turner
Journal:  J Med Genet       Date:  1974-06       Impact factor: 6.318

3.  Close linkage of the Wieacker-Wolff syndrome to the DNA segment DXYS1 in proximal Xq.

Authors:  P Wieacker; G Wolff; T F Wienker
Journal:  Am J Med Genet       Date:  1987-09

4.  Conference report: International Workshop on the fragile X and X-linked mental retardation.

Authors:  J M Opitz; G R Sutherland
Journal:  Am J Med Genet       Date:  1984-01

5.  Linkage studies in Menkes' disease. The Xg blood group system and C-banding of the X chromosome.

Authors:  N Horn; J Stene; A M Møllekaer; U Friedrich
Journal:  Ann Hum Genet       Date:  1984-05       Impact factor: 1.670

Review 6.  Nonsyndromic X-linked mental retardation: review and mapping of MRX29 to Xp21.

Authors:  B Häne; R J Schroer; J F Arena; H A Lubs; C E Schwartz; R E Stevenson
Journal:  Clin Genet       Date:  1996-10       Impact factor: 4.438

7.  Screening of mentally retarded males for macro-orchidism and the fragile X chromosome.

Authors:  P N Howard-Peebles; W H Finley
Journal:  Am J Med Genet       Date:  1983-08

8.  The diagnosis and frequency of X-linked conditions in a cohort of moderately retarded males with affected brothers.

Authors:  J Fishburn; G Turner; A Daniel; R Brookwell
Journal:  Am J Med Genet       Date:  1983-04

Review 9.  Nonspecific X-linked mental retardation I: a review with information from 24 new families.

Authors:  D S Herbst
Journal:  Am J Med Genet       Date:  1980

10.  Macroorchidism and fragile X in mentally retarded males. Clinical, cytogenetic, and some hormonal investigations in mentally retarded males, including two with the fragile site at Xq28, fra(X)(q28).

Authors:  K B Nielsen; N Tommerup; H V Dyggve; C Schou
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

View more
  5 in total

1.  Mutations in the BRWD3 gene cause X-linked mental retardation associated with macrocephaly.

Authors:  Michael Field; Patrick S Tarpey; Raffaella Smith; Sarah Edkins; Sarah O'Meara; Claire Stevens; Calli Tofts; Jon Teague; Adam Butler; Ed Dicks; Syd Barthorpe; Gemma Buck; Jennifer Cole; Kristian Gray; Kelly Halliday; Katy Hills; Andrew Jenkinson; David Jones; Andrew Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; David Richardson; Rebecca Shepherd; Alexandra Small; Jennifer Varian; Sofie West; Sara Widaa; Uma Mallya; Richard Wooster; Jenny Moon; Ying Luo; Helen Hughes; Marie Shaw; Kathryn L Friend; Mark Corbett; Gillian Turner; Michael Partington; John Mulley; Martin Bobrow; Charles Schwartz; Roger Stevenson; Jozef Gecz; Michael R Stratton; P Andrew Futreal; F Lucy Raymond
Journal:  Am J Hum Genet       Date:  2007-06-26       Impact factor: 11.025

2.  The phenotypic spectrum of ARHGEF9 includes intellectual disability, focal epilepsy and febrile seizures.

Authors:  Karl Martin Klein; Manuela Pendziwiat; Anda Eilam; Ronit Gilad; Ilan Blatt; Felix Rosenow; Moien Kanaan; Ingo Helbig; Zaid Afawi
Journal:  J Neurol       Date:  2017-06-15       Impact factor: 4.849

3.  ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation.

Authors:  Michael Alber; Vera M Kalscheuer; Elysa Marco; Elliott Sherr; Gaetan Lesca; Marianne Till; Gyri Gradek; Antje Wiesener; Christoph Korenke; Sandra Mercier; Felicitas Becker; Toshiyuki Yamamoto; Stephen W Scherer; Christian R Marshall; Susan Walker; Usha R Dutta; Ashwin B Dalal; Vanessa Suckow; Payman Jamali; Kimia Kahrizi; Hossein Najmabadi; Berge A Minassian
Journal:  Neurol Genet       Date:  2017-05-26

4.  Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABAA receptor α2 subunit.

Authors:  Dustin J Hines; April Contreras; Betsua Garcia; Jeffrey S Barker; Austin J Boren; Christelle Moufawad El Achkar; Stephen J Moss; Rochelle M Hines
Journal:  Mol Psychiatry       Date:  2022-02-15       Impact factor: 13.437

5.  Missense Mutation R338W in ARHGEF9 in a Family with X-linked Intellectual Disability with Variable Macrocephaly and Macro-Orchidism.

Authors:  Philip Long; Melanie M May; Victoria M James; Simone Grannò; John P Johnson; Patrick Tarpey; Roger E Stevenson; Kirsten Harvey; Charles E Schwartz; Robert J Harvey
Journal:  Front Mol Neurosci       Date:  2016-01-20       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.